Heading for the United States for the Dômes Pharma group, in Pont-du-Château (Puy-de-Dôme)

Growing across the Atlantic while strengthening our presence in Europe: this is the dual challenge that Dômes Pharma wants to take up. Already very present on the Old Continent with subsidiaries created in Great Britain then in Germany, the group based in Pont-du-Château, whose main production unit is not far away, in Lempdes, has prospered internationally. via its veterinary products and wants to follow this strategy by continuing to shine in its preferred market.

But the time has come to explore the largest animal health market in the world, that of the United States. This is the conviction of the president, Anne Moulin, who will invest herself in person to develop the American subsidiary, newly created but which is starting from scratch.

” Excited to be there “

“I can’t wait to be in the field,” she says, and to pack her bags to settle this summer in Boston, with her two children. The idea, to supervise the necessary development operations as closely as possible: preparations for the launch of the first Dômes Pharma product authorized in the United States, in 2024, to form a sales team to ensure distribution and to build a solid network in order to prospect with a view to of a possible acquisition, which would accelerate the establishment on this specific market.

Receive our eco newsletter by email and find the latest news from economic players in your region.

NL {“path”:”mini-inscription/MT_Decideur”,”accessCode”:”14144113″,”allowGCS”:”true”,”bodyClass”:”ripo_generic”,”contextLevel”:”KEEP_ALL”,”filterMotsCles”: “1|13|79|80|3219|6973″,”gabarit”:”generic”,”idArticle”:”4144113″,”idArticlesList”:”4144113″,”idDepartement”:”282″,”idZone”: “30603”,”Keywords”:”1|13|79|80|3219|6973″,”premium”:”true”,”pubs”:”top_banner|article”,”site”:”MT”,”subdomain “:”www”,”urlTitle”:”heading-for-the-united-states-for-the-domes-pharma-group-in-pont-du-chateau-puy-de-dome”}

External growth to save time is the strategy that Domes Pharma employed in Great Britain and which it was unable to deploy in Germany. A dual experience that should be used when tackling the specificities of the American market.

American shift without forgetting Europe

The president, at the helm of the group since 2016, is moving abroad for three or even four years and leaves her chair to her mother, Dominique Moulin, who sat on the supervisory board. It also and above all delegates the operational management of the group’s activities in Europe to Sébastien Boussemart, who becomes CEO. Arrived in 2018, he was previously in charge of business development operations. “He takes the leadership for Europe, it’s a logical continuation, believes Anne Moulin. Sébastien is a member of the executive committee and knows perfectly all our acquisition and development projects. »

Dômes Pharma extends its network from Puy-de-Dôme to Germany (September 2020)

Anne Moulin leaves the leadership of Dôme Pharma in Europe to Sébastien Boussemart. Photo Francis Campagnoni

In Spain with a hybrid model

Domes Pharma (82 million euros in turnover in 2021 and more than 400 employees now) produces medicines for humans and has, for example, relocated paracetamol production to Lempdes. But the group ensures its growth above all thanks to animal health, which accounts for two thirds of sales. It is already present across the Atlantic, in Canada, via a distributor that markets three products. But it is in the United States that the Puydômoise company intends to take a new step in the years to come. Without forgetting its roots. “In Europe, our new territory will be Spain with a hybrid model: a distributor who will promote our brand,” announces Anne Moulin. Then it will be Italy, Benelux, Scandinavia, with interesting potential. »

No Asia yet in sight, but beautiful fields of exploration. And development.

The Dômes Pharma foundation (Puy-de-Dôme) in support of animal mediation

Patrice Campo
[email protected]
Twitter: @patricelmt

.

Leave a Comment